Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system

Cancer Research

Volumn 67, Issue 7, 2007, Pages 2938-2943

  Pirollo, Kathleen F ^a   Rait, Antonina ^a   Zhou, Qi ^a   Sung, Hee Hwang ^a   Dagata, John A ^b   Zon, Gerald ^c   Hogrefe, Richard I ^c   Palchik, Guillermo ^a   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^c TriLink BioTechnologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; HISTIDINE; LYSINE; NANOPARTICLE; PEPTIDE; SMALL INTERFERING RNA; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESEARCH; FLUORESCENCE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SCANNING PROBE MICROSCOPY; TUMOR GROWTH; ANIMAL; BREAST TUMOR; DRUG SCREENING; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; METHODOLOGY; NUDE MOUSE; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE THERAPY; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NANOPARTICLES; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248228071     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4535     Document Type: Article

References (27)

1. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006;11:67-73.
2. Cejka D, Losert D, Wacheck V. Short interfering RNA (siRNA): tool or therapeutic? Clin Sci 2006;110:47-58.
3. Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol 2006;124:12-25.
4. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149.
5. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-17.
6. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92.
7. Morris KV, Rossi JJ. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther 2006;13:553-8.
8. Schiffelers RM, Mixson AJ, Ansari AM, et al. Transporting silence: design of carriers for siRNA to angiogenic endothelium. J Control Release 2005;109:5-14.
9. Xu L, Tang WH, Huang CC, et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 2001;7:723-34.
10. Xu L, Huang C-C, Huang W-Q, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 2002;1:337-46.
11. Pirollo KF, Dagata J, Wang P, et al. A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol Imaging 2006;5:41-52.
12. Yu W, Pirollo KF, Yu B, et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 2004;32:e48.
13. Pichon C, Roufai MB, Monsigny M, Midoux P. Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides. Nucleic Acids Res 2000;28:504-12.
14. Chen QR, Zhang L, Luther PW, Mixson AJ. Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res 2002;30:1338-45.
15. Pirollo KF, Zon G, Rait A, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006;17:117-24.
16. Leonessa F, Green D, Licht T, et al. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 1996;73:154-61.
17. Rait AS, Pirollo KF, Rait V et al. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther 2001;8:728-39.
18. Hogrefe RI, Lebedev AV, Zon G, et al. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 2006;25:889-907.
19. Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I, and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004;108:71-7.
20. Rait AS, Pirollo KF, Ulick D, Cullen K, Chang EH. HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann N Y Acad Sci 2003;1002:78-89.
21. Haynes BF, Hemler M, Cotner T, et al. Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol 1981;127:347-51.
22. Batra JK, Fitzgerald DJ, Chaudhary VK, Pastan I. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cell Biol 1991;11:2200-5.
23. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
24. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
25. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004;22:4217-26.
26. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 2005;31:151-74.
27. Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle 2006;5:824-8.